1-((3R,4S)-4-氨基-3-羟基-2,2-二甲基色满-6-基)乙酮 | 175133-79-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 中文名称: 1-((3R,4S)-4-氨基-3-羟基-2,2-二甲基色满-6-基)乙酮
• 英文名称: trans-6-Acetyl-4-amino-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran
• 英文别名: trans-6-acetyl-4-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol；1-((3R,4S)-4-Amino-3-hydroxy-2,2-dimethylchroman-6-YL)ethanone；1-[(3R,4S)-4-amino-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-6-yl]ethanone
• CAS: 175133-79-6
• 化学式: C₁₃H₁₇NO₃
• 分子量: 235.283
• InChiKey: AECGYOKFJFSDKI-NWDGAFQWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  72.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  对氟苯甲酰氯 、 1-((3R,4S)-4-氨基-3-羟基-2,2-二甲基色满-6-基)乙酮 在 三乙胺 作用下， 生成 N-[(3R,4S)-6-乙酰基-3,4-二氢-3-羟基-2,2-二甲基-2H-1-苯并吡喃-4-基]-4-氟-苯甲酰胺
  参考文献：
  名称：

  新型反式-4-（取代的苯甲酰胺基）-3,4-二氢-2H-苯并[b]-吡喃-3-醇衍生物的合成作为潜在的具有独特结合特征的抗惊厥药。

  摘要：

  DOI：

  10.1021/jm960535w
• 作为产物：
  描述：

  6-Acetyl-3,4-dihydro-2,2-dimethyl-3,4-epoxy-2H-benzo[b]pyran 在 氨 作用下， 以 乙醇 为溶剂， 生成 1-((3R,4S)-4-氨基-3-羟基-2,2-二甲基色满-6-基)乙酮
  参考文献：
  名称：

  4-（取代-羰基氨基）-2H-1-苯并吡喃的合成及降压活性。

  摘要：

  描述了口服给予有意识的自发性高血压大鼠的一系列新型4-（取代-羰基氨基）-2H-1-苯并吡喃-3-醇的合成和降压活性。对于具有在羰基侧翼的烷基，氨基或芳基的化合物，观察到最佳活性。在烷基和氨基系列中，最有效的化合物分别包含甲基和甲基氨基。已使用-86作为标记物，将几种类似物与cromakalim（1）对兔肠系膜动脉钾离子外流的作用进行了比较。每种化合物增强rub 86流出的能力与其降血压活性大致平行​​，因此这些类似物（如化合物（1））属于已归类为钾通道激活剂的一系列药物。

  DOI：

  10.1021/jm00171a051

文献信息

• Anti-hypertensive chromanol derivatives
  申请人：Beecham Group p.l.c.

  公开号：US04575511A1

  公开（公告）日：1986-03-11

  Compounds of formula (I): ##STR1## wherein: either one of R.sub.1 and R.sub.2 is hydrogen and the other is selected from the class of C.sub.1-6 alkylcarbonyl, C.sub.1-6 alkoxycarbonyl, C.sub.1-6 alkylcarbonyloxy, C.sub.1-6 alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, C.sub.1-6 alkylsulphinyl, C.sub.1-6 alkylsulphonyl, C.sub.1-6 alkoxysulphinyl, C.sub.1-6 alkoxysulphonyl, C.sub.1-6 alkylcarbonylamino, C.sub.1-6 alkoxycarbonylamino, C.sub.1-6 alkyl-thiocarbonyl, C.sub.1-6 alkoxy-thiocarbonyl, C.sub.1-6 alkyl-thiocarbonyloxy, C.sub.1-6 alkyl-thiolmethyl, formyl or aminosulphinyl, aminosulphonyl or aminocarbonyl, the amino moiety being optionally substituted by one or two C.sub.1-6 alkyl groups, or C.sub.1-6 alkoxysulphinylamino, C.sub.1-6 alkoxysulphonylamino C.sub.1-6 alkoxysulphinylamino or C.sub.1-6 alkoxysulphonylamino or ethylenyl terminally substituted by C.sub.1-6 alkylcarbonyl, nitro or cyano, or one of R.sub.1 and R.sub.2 is nitro, cyano or C.sub.1-3 alkylcarbonyl and the other is methoxy or amino optionally substituted by one or two C.sub.1-6 alkyl groups or by C.sub.2-7 alkanoyl; one of R.sub.3 and R.sub.4 is hydrogen or C.sub.1-4 alkyl and the other is C.sub.1-4 alkyl or R.sub.3 and R.sub.4 together are C.sub.2-5 polymethylene; either R.sub.5 is hydrogen, hydroxy, C.sub.1-6 alkoxy or C.sub.1-7 acyloxy and R.sub.6 is hydrogen or R.sub.5 and R.sub.6 together are a bond; R.sub.7 is selected from the class consisting of C.sub.1-6 alkyl substituted by amino optionally substituted by one or two C.sub.1-6 alkyl groups which may be the same or different; amino optionally substituted by a C.sub.1-6 alkyl or C.sub.1-6 alkenyl group or a C.sub.1-6 alkanoyl group optionally substituted by up to three halo atoms or by a phenyl group optionally substituted by C.sub.1-6 alkyl, C.sub.1-6 alkoxy or halogen; or C.sub.1-6 alkoxy, or phenoxy optionally substituted by C.sub.1-6 alkyl, C.sub.1-6 alkoxy or halogen; or, when X is oxygen, R.sub.7 is further selected from the class of carboxy, C.sub.1-6 alkoxycarbonyl, or aminocarbonyl optionally substituted by one or two C.sub.1-6 alkyl groups which may be the same or different; R.sub.8 is hydrogen or C.sub.1-6 alkyl; and X is oxygen or sulphur; the R.sub.8 --N--CX--R.sub.7 group being trans to the R.sub.5 group when R.sub.5 and R.sub.6 together are not a bond; or when the compound of formula (I) contains a salifiable group, pharmaceutically acceptable salts thereof, having pharmacological activity, a process for preparing them, pharmaceutical compositions containing them, and their use in the treatment of mammals.

  式(I)的化合物：其中：R.sub.1和R.sub.2中的任一个是氢，另一个选自C.sub.1-6烷基羰基，C.sub.1-6烷氧羰基，C.sub.1-6烷基羰氧基，C.sub.1-6烷基羟甲基，硝基，氰基，氯基，三氟甲基，C.sub.1-6烷基砜基，C.sub.1-6烷基磺酰基，C.sub.1-6烷氧基砜基，C.sub.1-6烷氧基磺酰基，C.sub.1-6烷基羰基氨基，C.sub.1-6烷氧羰基氨基，C.sub.1-6烷基硫代羰基，C.sub.1-6烷氧基硫代羰基，C.sub.1-6烷基硫代羰氧基，C.sub.1-6烷基硫代硫醇甲基，甲酰基或氨基砜基，氨基磺酰基或氨基羰基，氨基基团可选择地被一个或两个C.sub.1-6烷基取代，或C.sub.1-6烷氧基砜基氨基，C.sub.1-6烷氧基磺酰基氨基，C.sub.1-6烷氧基砜基氨基或C.sub.1-6烷氧基磺酰基氨基，或末端被C.sub.1-6烷基羰基，硝基或氰基取代的乙烯基；R.sub.1和R.sub.2中的一个是硝基，氰基或C.sub.1-3烷基羰基，另一个是甲氧基或氨基，可选择地被一个或两个C.sub.1-6烷基或C.sub.2-7烷酰基取代；R.sub.3和R.sub.4中的一个是氢或C.sub.1-4烷基，另一个是C.sub.1-4烷基或R.sub.3和R.sub.4一起是C.sub.2-5聚亚甲基；R.sub.5是氢，羟基，C.sub.1-6烷氧基或C.sub.1-7酰氧基，R.sub.6是氢或R.sub.5和R.sub.6一起是键合；R.sub.7选自经氨基取代的C.sub.1-6烷基，可选择地被一个或两个相同或不同的C.sub.1-6烷基取代；氨基，可选择地被C.sub.1-6烷基或C.sub.1-6烯基取代或可选择地被高达三个卤原子取代或被可选择地被C.sub.1-6烷基，C.sub.1-6烷氧基或卤原子取代的苯基取代；或C.sub.1-6烷氧基，或可选择地被C.sub.1-6烷基，C.sub.1-6烷氧基或卤原子取代的苯氧基；或当X为氧时，R.sub.7进一步选自羧基，C.sub.1-6烷氧羰基，或氨基羰基，可选择地被一个或两个相同或不同的C.sub.1-6烷基取代；R.sub.8是氢或C.sub.1-6烷基；X是氧或硫；当R.sub.5和R.sub.6一起不是键合时，R.sub.8--N--CX--R.sub.7基与R.sub.5基是反式的；或当式(I)的化合物含有可盐化基团时，其药理活性的药用盐，制备它们的方法，含有它们的药物组合物，以及它们在治疗哺乳动物中的用途。
• [EN] PRODRUG COMPOUNDS<br/>[FR] COMPOSÉS DE TYPE PROMÉDICAMENT
  申请人：PROXIMAGEN LTD

  公开号：WO2015097461A1

  公开（公告）日：2015-07-02

  A compound of formula (Ia) or (Ib), or a pharmaceutically acceptable salt thereof, Wherein Q, R2, Ar, A and R1 are as defined in claim 1. The claimed compounds are gap junction blockers useful for the treatment or prevention of a range of conditions including migraine, epilepsy, non-epileptic seizures, brain injury (including stroke, intracranial haemorrhage and trauma induced), pain, neurodegenerative disease or cardiovascular disease including myocardial infarction, coronary revascularization or angina.

  公式（Ia）或（Ib）的化合物，或其药学上可接受的盐，其中Q、R2、Ar、A和R1如权利要求1所定义。所述化合物是缝隙连接阻滞剂，可用于治疗或预防一系列疾病，包括偏头痛、癫痫、非癫痫性抽搐、脑损伤（包括中风、颅内出血和创伤引起的）、疼痛、神经退行性疾病或心血管疾病，包括心肌梗死、冠状动脉重建术或心绞痛。
• Treatment
  申请人：SmithKline Beecham p.l.c.

  公开号：US05760074A1

  公开（公告）日：1998-06-02

  The invention relates to certain cis and trans benzopyrans having substituted benzamides at position C-4 and to their use in treating and/or preventing certain CNS disorders.

  本发明涉及在C-4位置具有取代苯甲酰胺的顺式和反式苯并吡喃类化合物及其在治疗和/或预防某些中枢神经系统疾病中的应用。
• Substituted benzopyran derivatives and their use as anticonvulsants
  申请人：——

  公开号：US06395909B1

  公开（公告）日：2002-05-28

  This invention relates to 6-(hydroxyalkylcarbonyl) benzopyrans and their use as anticonvulsants.

  该发明涉及6-(羟基烷酰基)苯并吡喃及其作为抗癫痫药物的用途。
• Chroman and chromene derivatives
  申请人：BEECHAM GROUP PLC

  公开号：EP0126367A1

  公开（公告）日：1984-11-28

  Compounds of formula (I): wherein: either one of R1 and R2 is hydrogen and the other is selected from the class of C1-6 alkylcarbonyl, C1-6 alkoxycarbonyl, C1-6 alkylcarbonyloxy, C1-6 alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, C1-6 alkylsulphinyl, C1-6 alkylsulphonyl, C1-6 alkoxysulphinyl, C1-6 alkoxysulphonyl, C1-6 alkylcarbonylamino, C1-6 alkoxycarbonylamino, C1-6 alkyl-thiocarbonyl, C1-6 alkoxy-thiocarbonyl, C1-6 alkyl-thiocarbonyloxy, C1-6 alkyl-thiomethyl, formyl or aminosulphinyl, aminosulphonyl or aminocarbonyl, the amino moiety being optionally substituted by one or two C1-6 alkyl groups, or C1-6 alkylsulphinylamino, C1-6 alkylsulphonylamino, C1-6 alkoxysulphinylamino or C1-6 alkoxysulphonylamino or ethylenyl terminally substituted by Cl-6 alkylcarbonyl, nitro or cyano, or one of R1 and R2 is nitro, cyano or C1-3 alkylcarbonyl and the other is methoxy or amino optionally substituted by one or two C1-6 alkyl groups or by C2-7 alkanoyl; one of R3 and R4 is hydrogen or Cl-4 alkyl and the other is Cl-4 alkyl or R3 and R4 together are C2-5 polymethylene; either R5 is hydrogen, hydroxy, C1-6 alkoxy or C1-7 acyloxy and R6 is hydrogen or R5 and R6 together are a bond; R7 is selected from the class consisting of C1-6 alkyl substituted by amino optionally substituted by one or two C1-6 alkyl groups which may be the same or different; amino optionally substituted by a C1-6 alkyl or C1-6 alkenyl group or a C5-8 cycloalkyl group or by a phenyl group optionally substituted by C1-6 alkyl, Cl-6 alkoxy or halogen; or C1-6 alkoxy, or phenoxy optionally substituted by C1-6 alkyl, C1-6 alkoxy or halogen; or, when X is oxygen, R7 is selected from the class of carboxy, C1-6 alkoxycarbonyl, or aminocarbonyl optionally substituted by one or two C1-6 alkyl groups which may be the same or different; R8 is hydrogen or C1-6 alkyl; and X is oxygen or sulphur; The R8-N-CX-R7 group being trans to the R5 group when R5 and R6 together are not a bond; or when the compound of formula (I) contains a salifiable group, pharmaceutically acceptable salts thereof, having pharmacological activity, a process for preparing them, pharmaceutical compositions containing them, and their use in the treatment of mammals.

  式(I)化合物： 其中 R1 和 R2 中的任一个为氢，另一个选自 C1-6 烷基羰基、C1-6 烷氧基羰基、C1-6 烷基羰氧基、C1-6 烷基羟甲基、硝基、氰基、氯基、三氟甲基、C1-6 烷基亚磺酰基、C1-6 烷基磺酰基、C1-6 烷氧基磺酰基、C1-6 烷基羰基、C1-6 烷氧基磺酰基、C1-6 烷基羰基C1-6烷基磺酰基、C1-6烷氧基磺酰基、C1-6烷氧基磺酰基、C1-6烷基羰基氨基、C1-6烷氧基羰基氨基、C1-6烷基硫代羰基、C1-6烷氧基硫代羰基、C1-6烷基硫代羰氧基、C1-6烷基硫甲基、甲酰基或氨基磺酰基、氨基磺酰基或氨基羰基，氨基可选择被一个或两个 C1-6 烷基取代，或被 C1-6 烷基亚磺酰氨基、C1-6 烷基磺酰基氨基、C1-6 烷氧基亚磺酰氨基或 C1-6 烷氧基磺酰基氨基或被 Cl-6 烷基羰基最终取代的乙烯基、R1和R2中的一个是硝基、氰基或C1-3烷基羰基，另一个是甲氧基或被一个或两个C1-6烷基或C2-7烷酰基任选取代的氨基；R3 和 R4 中的一个是氢或 Cl-4 烷基，另一个是 Cl-4 烷基，或 R3 和 R4 合在一起是 C2-5 聚亚甲基；R5 是氢、羟基、C1-6 烷氧基或 C1-7 乙酰氧基，R6 是氢，或 R5 和 R6 合在一起是键；R7 选自由氨基任选取代的 C1-6 烷基组成的类别，氨基任选被一个或两个 C1-6 烷基取代，这两个 C1-6 烷基可以相同或不同；被 C1-6 烷基或 C1-6 烯基或 C5-8 环烷基或被 C1-6 烷基、Cl-6 烷氧基或卤素任选取代的苯基任选取代的氨基；或被 C1-6 烷基、C1-6 烷氧基或卤素任选取代的 C1-6 烷氧基或苯氧基；或当 X 为氧时，R7 选自被一个或两个可能相同或不同的 C1-6 烷基任选取代的羧基、C1-6 烷氧基羰基或氨基羰基； R8 是氢或 C1-6 烷基；以及 X 是氧或硫； 当 R5 和 R6 合在一起不是键时，R8-N-CX-R7 基团反式为 R5 基团； 或当式(I)化合物含有可盐基团时，具有药理活性的其药学上可接受的盐、制备它们的工艺、含有它们的药物组合物，以及它们在治疗哺乳动物中的用途。